Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Influenza virus N-linked glycosylation and innate immunity.

York IA, Stevens J, Alymova IV.

Biosci Rep. 2019 Jan 8;39(1). pii: BSR20171505. doi: 10.1042/BSR20171505. Print 2019 Jan 31. Review.

2.

Longevity of adenovirus vector immunity in mice and its implications for vaccine efficacy.

Sayedahmed EE, Kumari R, Shukla S, Hassan AO, Mohammed SI, York IA, Gangappa S, Sambhara S, Mittal SK.

Vaccine. 2018 Oct 29;36(45):6744-6751. doi: 10.1016/j.vaccine.2018.09.031. Epub 2018 Sep 25.

PMID:
30266488
3.

Biosensor-based epitope mapping of antibodies targeting the hemagglutinin and neuraminidase of influenza A virus.

Guo Z, Wilson JR, York IA, Stevens J.

J Immunol Methods. 2018 Oct;461:23-29. doi: 10.1016/j.jim.2018.07.007. Epub 2018 Jul 24. Review.

PMID:
30053389
4.

Virulent PB1-F2 residues: effects on fitness of H1N1 influenza A virus in mice and changes during evolution of human influenza A viruses.

Alymova IV, McCullers JA, Kamal RP, Vogel P, Green AM, Gansebom S, York IA.

Sci Rep. 2018 May 10;8(1):7474. doi: 10.1038/s41598-018-25707-y.

5.

Evolution and Virulence of Influenza A Virus Protein PB1-F2.

Kamal RP, Alymova IV, York IA.

Int J Mol Sci. 2017 Dec 29;19(1). pii: E96. doi: 10.3390/ijms19010096. Review.

6.

An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody protects mice from morbidity without interfering with the development of protective immunity to subsequent homologous challenge.

Wilson JR, Belser JA, DaSilva J, Guo Z, Sun X, Gansebom S, Bai Y, Stark TJ, Chang J, Carney P, Levine MZ, Barnes J, Stevens J, Maines TR, Tumpey TM, York IA.

Virology. 2017 Nov;511:214-221. doi: 10.1016/j.virol.2017.08.016. Epub 2017 Sep 6.

7.

Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.

Kamal RP, Blanchfield K, Belser JA, Music N, Tzeng WP, Holiday C, Burroughs A, Sun X, Maines TR, Levine MZ, York IA.

J Virol. 2017 Sep 27;91(20). pii: e01202-17. doi: 10.1128/JVI.01202-17. Print 2017 Oct 15.

8.

Stockpiled pre-pandemic H5N1 influenza virus vaccines with AS03 adjuvant provide cross-protection from H5N2 clade 2.3.4.4 virus challenge in ferrets.

Sun X, Belser JA, Pulit-Penaloza JA, Creager HM, Guo Z, Jefferson SN, Liu F, York IA, Stevens J, Maines TR, Jernigan DB, Katz JM, Levine MZ, Tumpey TM.

Virology. 2017 Aug;508:164-169. doi: 10.1016/j.virol.2017.05.010. Epub 2017 May 26.

9.

Non-neutralizing antibodies induced by seasonal influenza vaccine prevent, not exacerbate A(H1N1)pdm09 disease.

Kim JH, Reber AJ, Kumar A, Ramos P, Sica G, Music N, Guo Z, Mishina M, Stevens J, York IA, Jacob J, Sambhara S.

Sci Rep. 2016 Nov 16;6:37341. doi: 10.1038/srep37341.

10.

Glycosylation changes in the globular head of H3N2 influenza hemagglutinin modulate receptor binding without affecting virus virulence.

Alymova IV, York IA, Air GM, Cipollo JF, Gulati S, Baranovich T, Kumar A, Zeng H, Gansebom S, McCullers JA.

Sci Rep. 2016 Oct 31;6:36216. doi: 10.1038/srep36216.

11.

An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody with prophylactic and therapeutic activity in vivo.

Wilson JR, Guo Z, Reber A, Kamal RP, Music N, Gansebom S, Bai Y, Levine M, Carney P, Tzeng WP, Stevens J, York IA.

Antiviral Res. 2016 Nov;135:48-55. doi: 10.1016/j.antiviral.2016.10.001. Epub 2016 Oct 3.

12.

Antibody-Dependent Cell-Mediated Cytotoxicity to Hemagglutinin of Influenza A Viruses After Influenza Vaccination in Humans.

Zhong W, Liu F, Wilson JR, Holiday C, Li ZN, Bai Y, Tzeng WP, Stevens J, York IA, Levine MZ.

Open Forum Infect Dis. 2016 May 18;3(2):ofw102. doi: 10.1093/ofid/ofw102. eCollection 2016 Apr.

13.

Peripheral Leukocyte Migration in Ferrets in Response to Infection with Seasonal Influenza Virus.

Music N, Reber AJ, Kim JH, York IA.

PLoS One. 2016 Jun 17;11(6):e0157903. doi: 10.1371/journal.pone.0157903. eCollection 2016.

14.

RIG-I ligand enhances the immunogenicity of recombinant H7HA protein.

Cao W, Liepkalns JS, Kamal RP, Reber AJ, Kim JH, Hofstetter AR, Amoah S, Stevens J, Ranjan P, Gangappa S, York IA, Sambhara S.

Cell Immunol. 2016 Jun-Jul;304-305:55-8. doi: 10.1016/j.cellimm.2016.04.004. Epub 2016 Apr 9.

15.

A highly immunogenic vaccine against A/H7N9 influenza virus.

Cao W, Liepkalns JS, Hassan AO, Kamal RP, Hofstetter AR, Amoah S, Kim JH, Reber AJ, Stevens J, Katz JM, Gangappa S, York IA, Mittal SK, Sambhara S.

Vaccine. 2016 Feb 3;34(6):744-9. doi: 10.1016/j.vaccine.2015.12.062. Epub 2016 Jan 4.

16.

Supplementation of H1N1pdm09 split vaccine with heterologous tandem repeat M2e5x virus-like particles confers improved cross-protection in ferrets.

Music N, Reber AJ, Kim MC, York IA, Kang SM.

Vaccine. 2016 Jan 20;34(4):466-473. doi: 10.1016/j.vaccine.2015.12.023. Epub 2015 Dec 19.

17.

Diverse antigenic site targeting of influenza hemagglutinin in the murine antibody recall response to A(H1N1)pdm09 virus.

Wilson JR, Guo Z, Tzeng WP, Garten RJ, Xiyan X, Blanchard EG, Blanchfield K, Stevens J, Katz JM, York IA.

Virology. 2015 Nov;485:252-62. doi: 10.1016/j.virol.2015.08.004. Epub 2015 Aug 27.

18.

Emergence of Highly Pathogenic Avian Influenza A(H5N1) Virus PB1-F2 Variants and Their Virulence in BALB/c Mice.

Kamal RP, Kumar A, Davis CT, Tzeng WP, Nguyen T, Donis RO, Katz JM, York IA.

J Virol. 2015 Jun;89(11):5835-46. doi: 10.1128/JVI.03137-14. Epub 2015 Mar 18.

19.

An MHC class I immune evasion gene of Marek׳s disease virus.

Hearn C, Preeyanon L, Hunt HD, York IA.

Virology. 2015 Jan 15;475:88-95. doi: 10.1016/j.virol.2014.11.008. Epub 2014 Nov 27.

20.

Non-avian animal reservoirs present a source of influenza A PB1-F2 proteins with novel virulence-enhancing markers.

Alymova IV, York IA, McCullers JA.

PLoS One. 2014 Nov 4;9(11):e111603. doi: 10.1371/journal.pone.0111603. eCollection 2014.

21.

Recombinant influenza H7 hemagglutinins induce lower neutralizing antibody titers in mice than do seasonal hemagglutinins.

Blanchfield K, Kamal RP, Tzeng WP, Music N, Wilson JR, Stevens J, Lipatov AS, Katz JM, York IA.

Influenza Other Respir Viruses. 2014 Nov;8(6):628-35. doi: 10.1111/irv.12285. Epub 2014 Sep 12.

22.

Molecular determinants of influenza virus pathogenesis in mice.

Kamal RP, Katz JM, York IA.

Curr Top Microbiol Immunol. 2014;385:243-74. doi: 10.1007/82_2014_388. Review.

23.

Influenza vaccination accelerates recovery of ferrets from lymphopenia.

Music N, Reber AJ, Lipatov AS, Kamal RP, Blanchfield K, Wilson JR, Donis RO, Katz JM, York IA.

PLoS One. 2014 Jun 26;9(6):e100926. doi: 10.1371/journal.pone.0100926. eCollection 2014.

24.

Diversity of the murine antibody response targeting influenza A(H1N1pdm09) hemagglutinin.

Wilson JR, Tzeng WP, Spesock A, Music N, Guo Z, Barrington R, Stevens J, Donis RO, Katz JM, York IA.

Virology. 2014 Jun;458-459:114-24. doi: 10.1016/j.virol.2014.04.011. Epub 2014 May 10.

25.

LABEL: fast and accurate lineage assignment with assessment of H5N1 and H9N2 influenza A hemagglutinins.

Shepard SS, Davis CT, Bahl J, Rivailler P, York IA, Donis RO.

PLoS One. 2014 Jan 23;9(1):e86921. doi: 10.1371/journal.pone.0086921. eCollection 2014.

26.

Endoplasmic reticulum aminopeptidase-1 alleles associated with increased risk of ankylosing spondylitis reduce HLA-B27 mediated presentation of multiple antigens.

Seregin SS, Rastall DP, Evnouchidou I, Aylsworth CF, Quiroga D, Kamal RP, Godbehere-Roosa S, Blum CF, York IA, Stratikos E, Amalfitano A.

Autoimmunity. 2013 Dec;46(8):497-508. doi: 10.3109/08916934.2013.819855. Epub 2013 Sep 13.

27.

Evolution of highly pathogenic avian influenza (H5N1) virus populations in Vietnam between 2007 and 2010.

Nguyen T, Rivailler P, Davis CT, Hoa do T, Balish A, Dang NH, Jones J, Vui DT, Simpson N, Huong NT, Shu B, Loughlin R, Ferdinand K, Lindstrom SE, York IA, Klimov A, Donis RO.

Virology. 2012 Oct 25;432(2):405-16. doi: 10.1016/j.virol.2012.06.021. Epub 2012 Jul 20.

28.

A distinct lineage of influenza A virus from bats.

Tong S, Li Y, Rivailler P, Conrardy C, Castillo DA, Chen LM, Recuenco S, Ellison JA, Davis CT, York IA, Turmelle AS, Moran D, Rogers S, Shi M, Tao Y, Weil MR, Tang K, Rowe LA, Sammons S, Xu X, Frace M, Lindblade KA, Cox NJ, Anderson LJ, Rupprecht CE, Donis RO.

Proc Natl Acad Sci U S A. 2012 Mar 13;109(11):4269-74. doi: 10.1073/pnas.1116200109. Epub 2012 Feb 27.

29.

Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37.

Barlow PG, Svoboda P, Mackellar A, Nash AA, York IA, Pohl J, Davidson DJ, Donis RO.

PLoS One. 2011;6(10):e25333. doi: 10.1371/journal.pone.0025333. Epub 2011 Oct 21.

30.

The virulence of 1997 H5N1 influenza viruses in the mouse model is increased by correcting a defect in their NS1 proteins.

Spesock A, Malur M, Hossain MJ, Chen LM, Njaa BL, Davis CT, Lipatov AS, York IA, Krug RM, Donis RO.

J Virol. 2011 Jul;85(14):7048-58. doi: 10.1128/JVI.00417-11. Epub 2011 May 18.

31.

Structural basis for antigenic peptide precursor processing by the endoplasmic reticulum aminopeptidase ERAP1.

Nguyen TT, Chang SC, Evnouchidou I, York IA, Zikos C, Rock KL, Goldberg AL, Stratikos E, Stern LJ.

Nat Struct Mol Biol. 2011 May;18(5):604-13. doi: 10.1038/nsmb.2021. Epub 2011 Apr 10.

32.

Cutting Edge: Coding single nucleotide polymorphisms of endoplasmic reticulum aminopeptidase 1 can affect antigenic peptide generation in vitro by influencing basic enzymatic properties of the enzyme.

Evnouchidou I, Kamal RP, Seregin SS, Goto Y, Tsujimoto M, Hattori A, Voulgari PV, Drosos AA, Amalfitano A, York IA, Stratikos E.

J Immunol. 2011 Feb 15;186(4):1909-13. doi: 10.4049/jimmunol.1003337. Epub 2011 Jan 17.

33.

Placental leucine aminopeptidase efficiently generates mature antigenic peptides in vitro but in patterns distinct from endoplasmic reticulum aminopeptidase 1.

Georgiadou D, Hearn A, Evnouchidou I, Chroni A, Leondiadis L, York IA, Rock KL, Stratikos E.

J Immunol. 2010 Aug 1;185(3):1584-92. doi: 10.4049/jimmunol.0902502. Epub 2010 Jun 30.

34.

Identification of a critical T(Q/D/E)x5ADx2(I/L) motif from primate lentivirus Vif proteins that regulate APOBEC3G and APOBEC3F neutralizing activity.

Dang Y, Wang X, York IA, Zheng YH.

J Virol. 2010 Sep;84(17):8561-70. doi: 10.1128/JVI.00960-10. Epub 2010 Jun 30.

35.

Characterizing the specificity and cooperation of aminopeptidases in the cytosol and endoplasmic reticulum during MHC class I antigen presentation.

Hearn A, York IA, Bishop C, Rock KL.

J Immunol. 2010 May 1;184(9):4725-32. doi: 10.4049/jimmunol.0903125. Epub 2010 Mar 29.

36.

Identification of 81LGxGxxIxW89 and 171EDRW174 domains from human immunodeficiency virus type 1 Vif that regulate APOBEC3G and APOBEC3F neutralizing activity.

Dang Y, Davis RW, York IA, Zheng YH.

J Virol. 2010 Jun;84(11):5741-50. doi: 10.1128/JVI.00079-10. Epub 2010 Mar 24.

37.

Analysis of the role of tripeptidyl peptidase II in MHC class I antigen presentation in vivo.

Kawahara M, York IA, Hearn A, Farfan D, Rock KL.

J Immunol. 2009 Nov 15;183(10):6069-77. doi: 10.4049/jimmunol.0803564. Epub 2009 Oct 19.

38.

The specificity of trimming of MHC class I-presented peptides in the endoplasmic reticulum.

Hearn A, York IA, Rock KL.

J Immunol. 2009 Nov 1;183(9):5526-36. doi: 10.4049/jimmunol.0803663. Epub 2009 Oct 14.

39.
40.

Puromycin-sensitive aminopeptidase limits MHC class I presentation in dendritic cells but does not affect CD8 T cell responses during viral infections.

Towne CF, York IA, Neijssen J, Karow ML, Murphy AJ, Valenzuela DM, Yancopoulos GD, Neefjes JJ, Rock KL.

J Immunol. 2008 Feb 1;180(3):1704-12.

41.

Analysis of the role of bleomycin hydrolase in antigen presentation and the generation of CD8 T cell responses.

Towne CF, York IA, Watkin LB, Lazo JS, Rock KL.

J Immunol. 2007 Jun 1;178(11):6923-30.

42.
43.

Endoplasmic reticulum aminopeptidase 1 (ERAP1) trims MHC class I-presented peptides in vivo and plays an important role in immunodominance.

York IA, Brehm MA, Zendzian S, Towne CF, Rock KL.

Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9202-7. Epub 2006 Jun 5.

44.

Leucine aminopeptidase is not essential for trimming peptides in the cytosol or generating epitopes for MHC class I antigen presentation.

Towne CF, York IA, Neijssen J, Karow ML, Murphy AJ, Valenzuela DM, Yancopoulos GD, Neefjes JJ, Rock KL.

J Immunol. 2005 Nov 15;175(10):6605-14.

45.

A mutant cell with a novel defect in MHC class I quality control.

York IA, Grant EP, Dahl AM, Rock KL.

J Immunol. 2005 Jun 1;174(11):6839-46.

46.

Post-proteasomal antigen processing for major histocompatibility complex class I presentation.

Rock KL, York IA, Goldberg AL.

Nat Immunol. 2004 Jul;5(7):670-7. Review.

PMID:
15224092
47.

The cytosolic endopeptidase, thimet oligopeptidase, destroys antigenic peptides and limits the extent of MHC class I antigen presentation.

York IA, Mo AX, Lemerise K, Zeng W, Shen Y, Abraham CR, Saric T, Goldberg AL, Rock KL.

Immunity. 2003 Mar;18(3):429-40.

48.

The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8-9 residues.

York IA, Chang SC, Saric T, Keys JA, Favreau JM, Goldberg AL, Rock KL.

Nat Immunol. 2002 Dec;3(12):1177-84. Epub 2002 Nov 18.

PMID:
12436110
49.

An IFN-gamma-induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I-presented peptides.

Saric T, Chang SC, Hattori A, York IA, Markant S, Rock KL, Tsujimoto M, Goldberg AL.

Nat Immunol. 2002 Dec;3(12):1169-76. Epub 2002 Nov 18.

PMID:
12436109
50.

Protein degradation and the generation of MHC class I-presented peptides.

Rock KL, York IA, Saric T, Goldberg AL.

Adv Immunol. 2002;80:1-70. Review.

PMID:
12078479

Supplemental Content

Support Center